Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510

Cancers (Basel). 2023 Feb 27;15(5):1485. doi: 10.3390/cancers15051485.

¹ Centre for Human Drug Research, 2333 CL Leiden, The Netherlands.
² Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
³ Charles River Laboratories Den Bosch B.V., 5231 DD Den Bosch, The Netherlands.
⁴ PIQUR Therapeutics AG, 4057 Basel, Switzerland.
⁵ MS Imaging Department, ImaBiotech, 59120 Lille, France.
⁶ Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.
⁷ Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
⁸ SCARLETRED Holding GmbH, 1030 Vienna, Austria.
⁹ Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.

Abstract

The authors wish to make the following corrections to this paper [...].